EFFECTS OF ANTIARRHYTHMIC AGENTS CLASSIFIED AS CLASS-III GROUP ON ISCHEMIA-INDUCED MYOCARDIAL DAMAGE IN CANINE HEARTS

被引:15
|
作者
SANO, T
SUGIYAMA, S
TAKI, K
HANAKI, Y
SHIMADA, Y
OZAWA, T
机构
[1] NAGOYA UNIV,FAC MED,DEPT BIOMED CHEM,SHOWA KU,NAGOYA,AICHI 466,JAPAN
[2] NAGOYA UNIV,FAC MED,DEPT ANESTHESIOL,NAGOYA,AICHI 466,JAPAN
[3] NAGOYA UNIV,FAC MED,DEPT INTERNAL MED,NAGOYA,AICHI 466,JAPAN
关键词
D O I
10.1111/j.1476-5381.1990.tb12971.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cardioprotective effects of antiarrhythmic agents classified as class III, amiodarone, sotalol and E-4031, were investigated in anaesthetized dogs. The left anterior descending coronary artery was occluded for 2 h. Heart mitochondria were prepared from both the ischaemic and non-ischaemic areas, and their function was estimated polarographically. Activities of the lysosomal enzymes, N-acetyl-β-glucosaminidase and β-glucuronidase, were measured in each fraction. Two hour occlusion induced ventricular arrhythmias, and amiodarone, sotalol and E-4031 greatly suppressed the development of arrhythmias. Amiodarone, sotalol and E-4031 significantly protected mitochondria against ischaemia, and prevented ischaemia-induced leakage of lysosomal enzymes. Antiarrhythmic agents classified as class III show cardioprotective effects, which might participate in their antiarrhythmic effect.
引用
收藏
页码:577 / 581
页数:5
相关论文
共 43 条
  • [21] EFFECTS OF THE NEW CLASS-III ANTIARRHYTHMIC DRUG E-4031 ON MYOCARDIAL-CONTRACTILITY AND ELECTROPHYSIOLOGICAL PARAMETERS
    WETTWER, E
    SCHOLTYSIK, G
    SCHAAD, A
    HIMMEL, H
    RAVENS, U
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 (03) : 480 - 487
  • [22] DIFFERENTIAL-EFFECTS OF CLASS-I AND CLASS-III ANTIARRHYTHMIC DRUGS ON REENTRY IN A CHRONIC CANINE MODEL OF ATRIAL-FLUTTER
    FRAME, VB
    COLATSKY, TJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (02) : A156 - A156
  • [23] IMPROVEMENT OF ISCHEMIA REPERFUSION-INDUCED CONTRACTILE DYSFUNCTION OF PERFUSED HEARTS BY CLASS-IC ANTIARRHYTHMIC AGENTS
    LIU, JX
    TANONAKA, K
    OHTSUKA, Y
    SAKAI, Y
    TAKEO, S
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1993, 266 (03): : 1247 - 1254
  • [24] COMPARISON OF BINDING TO RAPIDLY ACTIVATING DELAYED RECTIFIER K+ CHANNEL, I-KR, AND EFFECTS ON MYOCARDIAL REFRACTORINESS FOR CLASS-III ANTIARRHYTHMIC AGENTS
    LYNCH, JJ
    BASKIN, EP
    NUTT, EM
    GUINOSSO, PJ
    HAMILL, T
    SALATA, JJ
    WOODS, CM
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 (02) : 336 - 340
  • [25] COMPARISON OF EFFECTS OF CLASS-I AND CLASS-III CARDIAC ANTIARRHYTHMIC AGENTS ON EXTRACELLULAR ACTION-POTENTIALS OF PERIPHERAL-NERVE
    MALLOY, KJ
    FRICK, GS
    FASEB JOURNAL, 1988, 2 (05): : A1556 - A1556
  • [26] EFFECT OF A CLASS-III ANTIARRHYTHMIC, UK-68798, ON CARDIAC-FUNCTION IN EXERCISE-INDUCED ISCHEMIA IN THE CONSCIOUS DOG
    GOUT, B
    JEAN, J
    BRIL, A
    FASEB JOURNAL, 1991, 5 (05): : A1215 - A1215
  • [27] EFFECT OF IBUTILIDE, A NEW CLASS-III AGENT, ON SUSTAINED ATRIAL-FIBRILLATION IN A CANINE MODEL OF ACUTE-ISCHEMIA AND MYOCARDIAL DYSFUNCTION INDUCED BY MICROEMBOLIZATION
    NABIH, MA
    PRCEVSKI, P
    FROMM, BS
    LAVINE, SJ
    ELNABTITY, M
    MUNIR, A
    STEINMAN, RT
    MEISSNER, MD
    LEHMANN, MH
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1993, 16 (10): : 1975 - 1983
  • [28] DIURETICS POTENTIATE MONOPHASIC ACTION-POTENTIAL PROLONGING EFFECTS OF CLASS-III ANTIARRHYTHMIC DRUGS IN ISOLATED GUINEA-PIG HEARTS
    TURGEON, J
    LESSARD, E
    BUSSIERE, S
    GROLEAU, MF
    DALEAU, P
    CIRCULATION, 1994, 90 (04) : 249 - 249
  • [29] EFFECTS OF THE CLASS-III ANTIARRHYTHMIC AGENT E-4031 ON GUINEA-PIG PAPILLARY-MUSCLE IN SIMULATED ISCHEMIA
    NEMETH, M
    PAPP, JG
    PHARMACOLOGICAL RESEARCH, 1992, 25 : 154 - 155
  • [30] ELECTROPHYSIOLOGIC EFFECTS OF E-4031, A CLASS-III ANTIARRHYTHMIC AGENT, ON REENTRANT VENTRICULAR ARRHYTHMIAS IN A CANINE 7-DAY-OLD MYOCARDIAL-INFARCTION MODEL
    KATOH, H
    OGAWA, S
    FURUNO, I
    SATO, Y
    YOH, S
    SAEKI, K
    NAKAMURA, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1990, 253 (03): : 1077 - 1082